Search

Your search keyword '"Larsen, Thomas Stauffer"' showing total 433 results
Start Over Author "Larsen, Thomas Stauffer"
433 results on '"Larsen, Thomas Stauffer"'

51. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation

Author

Campbell, Peter J., Baxter, E. Joanna, Beer, Philip A., Scott, Linda M., Bench, Anthony J., Huntly, Brian J.P., Erber, Wendy N., Kusec, Rajko, Larsen, Thomas Stauffer, Giraudier, Stéphane, Le Bousse-Kerdilès, Marie-Caroline, Griesshammer, Martin, Reilly, John T., Cheung, Betty Y., Harrison, Claire N., and Green, Anthony R.

Published
2006
Full Text
View/download PDF

53. 444 MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination

Author

Gigoux, Mathieu, primary, Zappasodi, Roberta, additional, Park, Joseph, additional, Pourpe, Stephane, additional, Ghosh, Arnab, additional, Bozkus, Cansu Cimen, additional, Mangarin, Levi, additional, Redmond, David, additional, Verma, Svena, additional, Schad, Sara, additional, Duke, William, additional, Jan, Max, additional, Leventhal, Matthew, additional, Ho, Vincent, additional, Hobbs, Gabriela, additional, Knudsen, Trine Alma, additional, Skov, Vibe, additional, Kjær, Lasse, additional, Larsen, Thomas Stauffer, additional, Hansen, Dennis Lund, additional, Coleman Lindsley, R, additional, Hasselbalch, Hans, additional, Grauslund, Jacob, additional, Andersen, Mads, additional, Holmström, Morten, additional, Chan, Timothy, additional, Rampal, Raajit, additional, Abdel-Wahab, Omar, additional, Bhardwaj, Nina, additional, Wolchok, Jedd, additional, Mullally, Ann, additional, and Merghoub, Taha, additional

Published
2020
Full Text
View/download PDF

54. Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84)

Author

Lugtenburg, Pieternella Johanna, primary, de Nully Brown, Peter, additional, van der Holt, Bronno, additional, D’Amore, Francesco A., additional, Koene, Harry R., additional, de Jongh, Eva, additional, Fijnheer, Rob, additional, van Esser, Joost W., additional, Böhmer, Lara H., additional, Pruijt, Johannes F., additional, Verhoef, Gregor E., additional, Hoogendoorn, Mels, additional, Bilgin, Memis Y., additional, Nijland, Marcel, additional, van der Burg-de Graauw, Nicole C., additional, Oosterveld, Margreet, additional, Jie, Kon-Siong G., additional, Larsen, Thomas Stauffer, additional, van der Poel, Marjolein W., additional, Leijs, Maria B., additional, Silbermann, Matthijs H., additional, van Marwijk Kooy, Marinus, additional, Beeker, Aart, additional, Kersten, Marie J., additional, Doorduijn, Jeanette K., additional, Tick, Lidwine W., additional, Brouwer, Rolf E., additional, Lam, King H., additional, Burggraaff, Coreline N., additional, de Keizer, Bart, additional, Arens, Anne I., additional, de Jong, Daphne, additional, Hoekstra, Otto S., additional, and Zijlstra-Baalbergen, Josée M., additional

Published
2020
Full Text
View/download PDF

56. Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study

Author

Sørensen, Anders Lindholm, primary, Mikkelsen, Stine Ulrik, additional, Knudsen, Trine Alma, additional, Bjørn, Mads Emil, additional, Andersen, Christen Lykkegaard, additional, Bjerrum, Ole Weis, additional, Brochmann, Nana, additional, Patel, Dustin Andersen, additional, Gjerdrum, Lise Mette Rahbek, additional, El Fassi, Daniel, additional, Kruse, Torben A., additional, Larsen, Thomas Stauffer, additional, Mourits-Andersen, Hans Torben, additional, Nielsen, Claus Henrik, additional, Ellervik, Christina, additional, Pallisgaard, Niels, additional, Thomassen, Mads, additional, Kjær, Lasse, additional, Skov, Vibe, additional, and Hasselbalch, Hans Carl, additional

Published
2020
Full Text
View/download PDF

57. Heteroclitic peptide cancer vaccine counters MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms

Author

Gigoux, Mathieu, primary, Zappasodi, Roberta, additional, Park, Joseph J, additional, Pourpe, Stephane, additional, Ghosh, Arnab, additional, Bozkus, Cansu Cimen, additional, Mangarin, Levi M.B., additional, Redmond, David, additional, Verma, Svena, additional, Schad, Sara, additional, Duke, William, additional, Leventhal, Matthew, additional, Jan, Max, additional, Ho, Vincent, additional, Hobbs, Gabriella, additional, Knudsen, Trine Alma, additional, Skov, Vibe, additional, Kjær, Lasse, additional, Larsen, Thomas Stauffer, additional, Hansen, Dennis Lund, additional, Lindsley, R Coleman, additional, Hasselbalch, Hans, additional, Grauslund, Jacob H, additional, Andersen, Mads H, additional, Holmström, Morten O, additional, Chan, Timothy, additional, Rampal, Raajit, additional, Abdel-Wahab, Omar, additional, Bhardwaj, Nina, additional, Wolchok, Jedd D, additional, Mullally, Ann, additional, and Merghoub, Taha, additional

Published
2020
Full Text
View/download PDF

60. SAFETY AND EFFICACY OF THE PD‐L1 INHIBITOR DURVALUMAB WITH R‐CHOP OR R2‐CHOP IN SUBJECTS WITH PREVIOUSLY UNTREATED, HIGH‐RISK DLBCL

Author

Nowakowski, Grzegorz S., Willenbacher, Wolfgang, Greil , R., Larsen, Thomas Stauffer, Patel, K., Jäger, U., Manges, R.F., Trumper, Lorenz, Haioun, C., Everaus, H, Kalakonda, N., Knoble, J., Brown, Peter de Nully, Jørgensen, J.M., Cunningham, D., Domper Rubio, N., Casadebaig, M., Manzke, O., and Munoz, J.

Published
2019
Full Text
View/download PDF

61. High risk of adverse events after autologous stem-cell transplantation in lymphoma patients with DNA repair pathway mutations: A nation-wide cohort study

Author

Husby, S., Favero, Francesco, Sørensen, B., Bæach, J., Hansen, J.W., Rodriguez‐Gonzalez, F.G., Arboe, B., Andersen, P.L., Haastrup , E.K., Fischer‐Nielsen, A., Sækmose, S.G., Hansen , P.B., Christiansen, I., Clasen-Linde, Erik, Knudsen, L.M., Grell, K., Segel, E.K., Ebbesen, L.H., Thorsgaard, M., Josefsson, P.L., El‐Galaly, T.C., Brown, Peter de Nully, Weischenfeldt, J., Larsen, Thomas Stauffer, and Grønbæk, K.

Published
2019

62. IMPACT OF SMOKING ON JAK2V617F ALLELE BURDEN AMONG PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS TREATED WITH PEGYLATED INTERFERON ALPHA-2 OR HYDROXYUREA IN THE DALIAH TRIAL

Author

Andersen Patel, Dustin, Knudsen, Trine Alma, Lund Hansen, Dennis, Ocias, Lucas Frans, Weiss Bjerrum, Ole, Brabrand, Mette, Ellervik, Christina, el Fassi, Daniel, Frederiksen, Mikael, Kjær, Lasse, Kielsgaard Kristensen, Thomas, Kruse, Torben A, Mourits-Andersen, Hans Torben, Møller, Peter, Overgaard, Ulrik Malthe, Severinsen, Marianne Tang, Skov, Vibe, Lindholm Sørensen, Anders, Jesper, Stentoft, Starklint, Jørn, de Stricker, Karin, Thomassen, Mads, Larsen, Thomas Stauffer, and Hasselbalch, Hans Carl

Published
2019

66. Ruxolitinib and interferon-alpha 2 combination therapy for patients with polycythemia vera or myelofibrosis:a phase II study

Author

Sorensen, Anders Lindholm, Mikkelsen, Stine Ulrik, Knudsen, Trine Alma, Bjorn, Mads Emil, Andersen, Christen Lykkegaard, Bjerrum, Ole Weis, Brochmann, Nana, Patel, Dustin Andersen, Gjerdrum, Lise Mette Rahbek, El Fassi, Daniel, Kruse, Torben A., Larsen, Thomas Stauffer, Mourits-Andersen, Hans Torben, Nielsen, Claus Henrik, Ellervik, Christina, Pallisgaard, Niels, Thomassen, Mads, Kjaer, Lasse, Skov, Vibe, Hasselbach, Hans Carl, Sorensen, Anders Lindholm, Mikkelsen, Stine Ulrik, Knudsen, Trine Alma, Bjorn, Mads Emil, Andersen, Christen Lykkegaard, Bjerrum, Ole Weis, Brochmann, Nana, Patel, Dustin Andersen, Gjerdrum, Lise Mette Rahbek, El Fassi, Daniel, Kruse, Torben A., Larsen, Thomas Stauffer, Mourits-Andersen, Hans Torben, Nielsen, Claus Henrik, Ellervik, Christina, Pallisgaard, Niels, Thomassen, Mads, Kjaer, Lasse, Skov, Vibe, and Hasselbach, Hans Carl

Abstract

We report the final 2-year end-of-study results from the first clinical trial investigating combination treatment with ruxolitinib and low-dose pegylated interferon-alpha 2 (PEG-IFN alpha 2). The study included 32 patients with polycythemia vera and 18 with primary or secondary myelofibrosis; 46 patients were previously intolerant of or refractory to PEG-IFN alpha 2. The primary outcome was efficacy, based on hematologic parameters, quality of life measurements, and JAK2 V617F allele burden. We used the 2013 European LeukemiaNet and International Working Group-Myeloproliferative Neoplasms Research and Treatment response criteria, including response in symptoms, splenomegaly, peripheral blood counts, and bone marrow. Of 32 patients with polycythemia vera, ten (31%) achieved a remission which was a complete remission in three (9%) cases. Of 18 patients with myelofibrosis, eight (44%) achieved a remission; five (28%) were complete remissions. The cumulative incidence of peripheral blood count remission was 0.85 and 0.75 for patients with polycythemia vera and myelofibrosis, respectively. The Myeloproliferative Neoplasm Symptom Assessment Form total symptom score decreased from 22 [95% confidence interval (95% CI):, 16-29] at baseline to 15 (95% CI: 10-22) after 2 years. The median JAK2 V617F allele burden decreased from 47% (95% CI: 33-61%) to 12% (95% CI: 6-22%), and 41% of patients achieved a molecular response. The drop-out rate was 6% among patients with polycythemia vera and 32% among those with myelofibrosis. Of 36 patients previously intolerant of PEG-IFN alpha 2, 31 (86%) completed the study, and 24 (67%) of these received PEG-IFN alpha 2 throughout the study. In conclusion, combination treatment improved cell counts, reduced bone marrow cellularity and fibrosis, decreased JAK2 V617F burden, and reduced symptom burden with acceptable toxicity in several patients with polycythemia vera or myelofibrosis. #EudraCT2013-003295-12.

Published
2020

67. Rituximab-chop with early rituximab intensification for diffuse large b-cell lymphoma: A randomized phase iii trial of the hovon and the nordic lymphoma group (hovon-84)

Author

MS Radiologie, Cancer, Lugtenburg, Pieternella Johanna, De Nully Brown, Peter, Van der Holt, Bronno, D'Amore, Francesco A., Koene, Harry R., De Jongh, Eva, Fijnheer, Rob, Van Esser, Joost W., Bohmer, Lara H., Pruijt, Johannes F., Verhoef, Gregor E., Hoogendoorn, Mels, Bilgin, Memis Y., Nijland, Marcel, Van der Burg-De Graauw, Nicole C., Oosterveld, Margreet, Jie, Kon Siong G., Larsen, Thomas Stauffer, Van der Poel, Marjolein W., Leijs, Maria B., Silbermann, Matthijs H., Van Marwijk Kooy, Marinus, Beeker, Aart, Kersten, Marie J., Doorduijn, Jeanette K., Tick, Lidwine W., Brouwer, Rolf E., Lam, King H., Burggraaff, Coreline N., De Keizer, Bart, Arens, Anne I., De Jong, Daphne, Hoekstra, Otto S., Zijlstra-Baalbergen, Josee M., MS Radiologie, Cancer, Lugtenburg, Pieternella Johanna, De Nully Brown, Peter, Van der Holt, Bronno, D'Amore, Francesco A., Koene, Harry R., De Jongh, Eva, Fijnheer, Rob, Van Esser, Joost W., Bohmer, Lara H., Pruijt, Johannes F., Verhoef, Gregor E., Hoogendoorn, Mels, Bilgin, Memis Y., Nijland, Marcel, Van der Burg-De Graauw, Nicole C., Oosterveld, Margreet, Jie, Kon Siong G., Larsen, Thomas Stauffer, Van der Poel, Marjolein W., Leijs, Maria B., Silbermann, Matthijs H., Van Marwijk Kooy, Marinus, Beeker, Aart, Kersten, Marie J., Doorduijn, Jeanette K., Tick, Lidwine W., Brouwer, Rolf E., Lam, King H., Burggraaff, Coreline N., De Keizer, Bart, Arens, Anne I., De Jong, Daphne, Hoekstra, Otto S., and Zijlstra-Baalbergen, Josee M.

Published
2020

68. The Prevalence of Diffuse Large B‐Cell Lymphoma Varies Substantially by Methods Applied: Results From a Population‐Based Study.

Author

Simonsen, Mikkel Runason, Jensen, Jonas Faartoft, Larsen, Thomas Stauffer, Gade, Inger‐Lise, Nully Brown, Peter, and El‐Galaly, Tarec Christoffer

Subjects
*DIFFUSE large B-cell lymphomas, *ORPHAN drugs, *DISEASE prevalence, *SURVIVAL rate, *RARE diseases
Abstract

ABSTRACT Objectives Methods Results Conclusions Accurate prevalence estimates of diffuse large B‐cell lymphoma (DLBCL) are important for numerous purposes including orphan drug designation. A key criterion for orphan drug designation is a disease prevalence of less than 5/10,000 persons. The objective is to apply and compare different methods of prevalence assessment.In the present nationwide Danish cohort study, the prevalence of DLBCL was assessed using different methodologies, including register‐based and formula‐based approaches.The prevalence calculations were based on 9,492 patients diagnosed with DLBCL since year 2000. Incidence increased and survival improved in the period, resulting in higher prevalence of DLBCL. In year 2023, the 2‐,3‐,5‐,10‐, and 20‐year prevalences were 1.53, 2.19, 3.45, 6.08, and 8.80 per 10,000 adults using the register‐based approach. The formula‐based approach was generally accurate when using restricted mean survival. However, when using median survival, the total prevalence was estimated at 8.1 per 10,000 adults. Furthermore, when extrapolating the median survival from the 5‐year survival under constant hazard assumption as done in some orphan drug designation reports, the prevalence was estimated at 6.6 per 10,000 adults.In conclusion, the estimated DLBCL prevalences are sensitive to the applied method. DLBCL would disqualify from orphan drug designation in some of the mentioned scenarios. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

69. Long-term Efficacy and Safety of Recombinant Interferon Alpha-2 vs. Hydroxyurea in Polycythemia Vera: Preliminary Results From the Three-Year Analysis of the DALIAH Trial – A Randomized Controlled Phase III Clinical Trial

Author

Knudsen, Trine Alma, Lund Hansen, Dennis, Ocias, Lukas Frans, Weiss Bjerrum, Ole, Brabrand, Mette, El Fassi, Daniel, Frederiksen, Mikael, Kjær, Lasse, Kielsgaard Kristensen, Thomas, Kruse, Torben A, Mourits-Andersen, Hans Torben, Møller, Peter, Overgaard, Ulrik Malthe, Severinsen, Marianne Tang, Skov, Vibe, Stentoft, Jesper, Starklint, Jørn, de Stricker, Karin, Thomassen, Mads, Larsen, Thomas Stauffer, and Hasselbalch, Hans Carl

Published
2018

70. Clinical Impact of Clonal Hematopoiesis after Autologous Stem Cell Transplantation for Lymphoma: A National Population-Based Study

Author

Husby, Simon, Favero, Francesco, Nielsen, Christian, Sørensen, Betina, Bæch, John, Hansen, Jakob W, G.R. Gonzalez, German, Arboe, Bente, Andersen, Lisbeth Pernille, K. Hastrup, Eva, Fischer, Anne, G. Sækmose, Susanne, Hansen, Per Boye, Christiansen, Ilse, Clasen-Linde, Erik, Meldgaard Knudsen, Lene, S. Davids, Matthew, Segel, Erik Kay, Ebbesen, Lene Hyldahl, Thorsgaard, Michael, Josefsson, Pär, El-Galaly, Tarec Christoffer, de Nully Brown, Peter, Weisenfeldt, Joachim, Larsen, Thomas Stauffer, and Grønbæk, Kirsten

Published
2018

71. Erratum to:Epigenetic changes in myelofibrosis: Distinct methylation changes in the myeloid compartments and in cases with ASXL1 mutations (Scientific Reports, (2017), 7, 1, (6774), 10.1038/s41598-017-07057-3)

Author

Nielsen, Helene Myrtue, Andersen, Christen Lykkegaard, Westman, Maj, Kristensen, Lasse Sommer, Asmar, Fazila, Kruse, Torben Arvid, Thomassen, Mads, Larsen, Thomas Stauffer, Skov, Vibe, Hansen, Lise Lotte, Bjerrum, Ole Weis, Hasselbalch, Hans Carl, Punj, Vasu, and Grønbæk, Kirsten

Abstract

In the original version of this Article, the authors Helene Myrtue Nielsen, Christen Lykkegaard Andersen, Lasse Sommer Kristensen, Torben Arvid Kruse, Thomas Stauffer Larsen, Lise Lotte Hansen, Ole Weis Bjerrum and Hans Carl Hasselbalch were incorrectly indexed. This error has now been corrected.

Published
2018
Full Text
View/download PDF

72. Publisher Correction:Epigenetic changes in myelofibrosis: Distinct methylation changes in the myeloid compartments and in cases with ASXL1 mutations (Scientific Reports, (2017), 7, 1, (6774), 10.1038/s41598-017-07057-3)

Author

Nielsen, Helene Myrtue, Andersen, Christen Lykkegaard, Westman, Maj, Kristensen, Lasse Sommer, Asmar, Fazila, Kruse, Torben Arvid, Thomassen, Mads, Larsen, Thomas Stauffer, Skov, Vibe, Hansen, Lise Lotte, Bjerrum, Ole Weis, Hasselbalch, Hans Carl, Punj, Vasu, and Grønbæk, Kirsten

Abstract

In the original version of this Article, the authors Helene Myrtue Nielsen, Christen Lykkegaard Andersen, Lasse Sommer Kristensen, Torben Arvid Kruse, Thomas Stauffer Larsen, Lise Lotte Hansen, Ole Weis Bjerrum and Hans Carl Hasselbalch were incorrectly indexed. This error has now been corrected.

Published
2018
Full Text
View/download PDF

73. Interim analysis of the Daliah trial - a randomized controlled phase iii clinical trial Comparing recombinant interferon alpha-2 vs. Hydroxyurea in MPN patients

Author

Knudsen, Trine Alma, Lund Hansen, Dennis, Ocias, Lukas Frans, Weiss Bjerrum, Ole, El Fassi, Daniel, Frederiksen, Mikael, Kjær, Lasse, Kielsgaard Kristensen, Thomas, Kruse, Torben A, Mourits-Andersen, Hans Torben, Møller, Peter, Overgaard, Ulrik Malthe, Severinsen, Marianne Tang, Skov, Vibe Henriette, Stentoft, Jesper, Starklint, Jørn, de Stricker, Karin, Thomassen, Mads, Larsen, Thomas Stauffer, and Hasselbalch, Hans Carl

Published
2018

74. Safety And Efficacy Of Combination Therapy Of Interferon Αlpha-2 And Ruxolitinib In Polycythemia Vera And Low-/Intermediate-1-Risk Myelofibrosis – A One Year Follow-Up Update Of A Phase II Study

Author

Mikkelsen, Stine Ulrik, Kjær, Lasse, Bjørn, Mads Emil, Knudsen, Trine Alma, Sørensen, Anders Lindholm, Skov, Vibe, Andersen, Christen Bertel Lykkegaard, Weiss Bjerrum, Ole, Brochmann Mortensen, Nana, El Fassi, Daniel, Kruse, Torben A, Larsen, Thomas Stauffer, Mourits-Andersen, Hans Torben, Nielsen, Claus Henrik, Pallisgaard, Niels, Thomassen, Mads, and Hasselbalch, Hans Carl

Published
2018

76. Genomic Profiling of a Phase III Clinical Trial of Interferon Versus Hydroxyurea in MPN Patients Reveals Mutation-Specific and Treatment-Specific Patterns of Response

Author

Knudsen, Trine Alma, primary, Skov, Vibe, additional, Werner, Lillian, additional, Duke, William, additional, Gibson, Christopher J., additional, Nag, Anwesha, additional, Thorner, Aaron R., additional, Wollison, Bruce, additional, Hansen, Dennis Lund, additional, Larsen, Thomas Stauffer, additional, Ellervik, Christina, additional, El Fassi, Daniel, additional, Stricker, Karin de, additional, Ocias, Lukas Frans, additional, Brabrand, Mette, additional, Bjerrum, Ole Weis, additional, Overgaard, Ulrik Malthe, additional, Frederiksen, Mikael, additional, Kristensen, Thomas Kielsgaard, additional, Kruse, Torben A, additional, Thomassen, Mads, additional, Mourits-Andersen, Torben, additional, Severinsen, Marianne Tang, additional, Stentoft, Jesper, additional, Starklint, Joern, additional, Møller, Peter, additional, Neuberg, Donna S, additional, Kjær, Lasse, additional, Hasselbalch, Hans, additional, Lindsley, R. Coleman, additional, and Mullally, Ann, additional

Published
2019
Full Text
View/download PDF

80. Safety and efficacy of PD-L1 inhibitor durvalumab with R-CHOP or R2-CHOP in subjects with previously untreated, high-risk DLBCL.

Author

Nowakowski, Grzegorz S., primary, Willenbacher, Wolfgang, additional, Greil, Richard, additional, Larsen, Thomas Stauffer, additional, Patel, Krish, additional, Jäger, Ulrich, additional, Manges, Robert F., additional, Trumper, Lorenz H., additional, Haioun, Corinne, additional, Everaus, Hele, additional, Kalakonda, Nagesh, additional, Knoble, Jeanna, additional, Brown, Peter, additional, Joergensen, Judit Meszaros, additional, Cunningham, David, additional, Domper, Neus, additional, Casadebaig, Marie-Laure, additional, Manzke, Oliver, additional, and Munoz, Javier, additional

Published
2019
Full Text
View/download PDF

82. The Impact of Pre-Therapeutic Hemoglobin Levels on the Outcome of Patients with Diffuse Large B-cell Lymphoma Treated with Anthracycline Containing Chemotherapy Before and After the Introduction of Rituximab: A Nation-Wide Cohort Study

Author

Clausen, Michael Roost, Ulrichsen, Sinna Pilgaard, Larsen, Thomas Stauffer, Himmelstrup, Bodil, Rønnov-Jessen, Dorthe, Pedersen, Per T., Madsen, Jakob, Pedersen, Robert Schou, Josefsson, Pär Lars, Gørløv, Jette Sønderskov, Nørgaard, Mette, and D'Amore, Francesco Annibale

Published
2017

83. Depth of neutrophil nadir after first cycle of R-CHOP predicts outcome in diffuse large B-cell lymphoma – a nationwide population-based cohort study

Author

Clausen, Michael Roost, primary, Ulrichsen, Sinna Pilgaard, additional, Larsen, Thomas Stauffer, additional, Poulsen, Christian B., additional, Tojaga, Selma, additional, Pedersen, Per Trøllund, additional, Madsen, Jakob, additional, Pedersen, Robert Schou, additional, Josefsson, Pär Lars, additional, Gørløv, Jette Sønderskov, additional, Nørgaard, Mette, additional, and d’Amore, Francesco, additional

Published
2019
Full Text
View/download PDF

85. Risk of Death, Relapse or Progression, and Loss of Life Expectancy at Different Progression-Free Survival Milestones in Primary Central Nervous System Lymphoma

Author

Biccler, Jorne Lionel, primary, Savage, Kerry J, additional, Brown, Peter de Nully, additional, Jørgensen, Judit, additional, Larsen, Thomas Stauffer, additional, Poulsen, Christian Bjørn, additional, Stoltenberg, Danny, additional, Jakobsen, Lasse H., additional, Bøgsted, Martin, additional, Villa, Diego, additional, and El-Galaly, Tarec C., additional

Published
2018
Full Text
View/download PDF

86. Interferon-alfa2 Treatment of Patients with Polycythemia Vera and Related Neoplasms Impacts Deregulation of Oxidative Stress Genes and Antioxidative Defence Mechanisms. Potential Implications of IFN-Alfa Induced Changes in TP53, NRF2 and CXCR4 for Genomic Instability and CD34+ Mobilisation

Author

Skov, Vibe, primary, Riley, Caroline, additional, Thomassen, Mads, additional, Kjær, Lasse, additional, Larsen, Thomas Stauffer, additional, Bjerrum, Ole Weis, additional, Kruse, Torben A, additional, and Hasselbalch, Hans Carl, additional

Published
2018
Full Text
View/download PDF

88. Clinical Impact of Clonal Hematopoiesis after Autologous Stem Cell Transplantation for Lymphoma: A National Population-Based Cohort Study

Author

Husby, Simon, primary, Francesco, Favero, additional, Nielsen, Christian, additional, Sørensen, Betina, additional, Bæch, John, additional, Hansen, Jakob Werner, additional, Gonzalez, German G.R., additional, Arboe, Bente, additional, Andersen, Lisbeth Pernille, additional, Hastrup, Eva Kannik, additional, Fischer-Nielsen, Anne, additional, Sækmose, Susanne G, additional, Hansen, Per Boye, additional, Christiansen, Ilse, additional, Clasen-Linde, Erik, additional, Knudsen, Lene Meldgaard, additional, Grell, Kathrine, additional, Segel, Erik Kay, additional, Ebbesen, Lene Hyldahl, additional, Thorsgaard, Michael, additional, Josefsson, Pär L., additional, El-Galaly, Tarec Christoffer, additional, Brown, Peter De Nully, additional, Weisenfeldt, Joachim, additional, Larsen, Thomas Stauffer, additional, and Grønbæk, Kirsten, additional

Published
2018
Full Text
View/download PDF

92. Long-Term Efficacy and Safety of Recombinant Interferon Alpha-2 Vs. Hydroxyurea in Polycythemia Vera: Preliminary Results from the Three-Year Analysis of the Daliah Trial - a Randomized Controlled Phase III Clinical Trial

Author

Knudsen, Trine Alma, primary, Hansen, Dennis Lund, additional, Ocias, Lukas Frans, additional, Bjerrum, Ole Weis, additional, Brabrand, Mette, additional, El Fassi, Daniel, additional, Frederiksen, Mikael, additional, Kjær, Lasse, additional, Kristensen, Thomas Kielsgaard, additional, Kruse, Torben A, additional, Mourits-Andersen, Torben, additional, Møller, Peter, additional, Overgaard, Ulrik Malthe, additional, Severinsen, Marianne Tang, additional, Skov, Vibe, additional, Stentoft, Jesper, additional, Starklint, Jørn, additional, de Stricker, Karin, additional, Thomassen, Mads, additional, Larsen, Thomas Stauffer, additional, and Hasselbalch, Hans Carl, additional

Published
2018
Full Text
View/download PDF

93. JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation

Author

Czech, Julia, primary, Cordua, Sabrina, additional, Weinbergerova, Barbora, additional, Baumeister, Julian, additional, Crepcia, Assja, additional, Han, Lijuan, additional, Maié, Tiago, additional, Costa, Ivan G., additional, Denecke, Bernd, additional, Maurer, Angela, additional, Schubert, Claudia, additional, Feldberg, Kristina, additional, Gezer, Deniz, additional, Brümmendorf, Tim H., additional, Müller-Newen, Gerhard, additional, Mayer, Jiri, additional, Racil, Zdenek, additional, Kubesova, Blanka, additional, Knudsen, Trine, additional, Sørensen, Anders L., additional, Holmström, Morten, additional, Kjær, Lasse, additional, Skov, Vibe, additional, Larsen, Thomas Stauffer, additional, Hasselbalch, Hans C., additional, Chatain, Nicolas, additional, and Koschmieder, Steffen, additional

Published
2018
Full Text
View/download PDF

94. Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis

Author

Mikkelsen, Stine Ulrik, primary, Kjaer, Lasse, additional, Bjørn, Mads Emil, additional, Knudsen, Trine Alma, additional, Sørensen, Anders Lindholm, additional, Andersen, Christen Bertel Lykkegaard, additional, Bjerrum, Ole Weis, additional, Brochmann, Nana, additional, Fassi, Daniel El, additional, Kruse, Torben A., additional, Larsen, Thomas Stauffer, additional, Mourits-Andersen, Hans Torben, additional, Nielsen, Claus Henrik, additional, Pallisgaard, Niels, additional, Thomassen, Mads, additional, Skov, Vibe, additional, and Hasselbalch, Hans Carl, additional

Published
2018
Full Text
View/download PDF

95. Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis

Author

Mikkelsen, Stine Ulrik, Kjaer, Lasse, Bjørn, Mads Emil, Knudsen, Trine Alma, Sørensen, Anders Lindholm, Andersen, Christen Bertel Lykkegaard, Bjerrum, Ole Weis, Brochmann, Nana, Fassi, Daniel El, Kruse, Torben A, Larsen, Thomas Stauffer, Mourits-Andersen, Hans Torben, Nielsen, Claus Henrik, Pallisgaard, Niels, Thomassen, Mads, Skov, Vibe, Hasselbalch, Hans Carl, Mikkelsen, Stine Ulrik, Kjaer, Lasse, Bjørn, Mads Emil, Knudsen, Trine Alma, Sørensen, Anders Lindholm, Andersen, Christen Bertel Lykkegaard, Bjerrum, Ole Weis, Brochmann, Nana, Fassi, Daniel El, Kruse, Torben A, Larsen, Thomas Stauffer, Mourits-Andersen, Hans Torben, Nielsen, Claus Henrik, Pallisgaard, Niels, Thomassen, Mads, Skov, Vibe, and Hasselbalch, Hans Carl

Abstract

Interferon-α2 reduces elevated blood cell counts and splenomegaly in patients with myeloproliferative neoplasms (MPN) and may restore polyclonal hematopoiesis. Its use is limited by inflammation-mediated toxicity, leading to treatment discontinuation in 10-30% of patients. Ruxolitinib, a potent anti-inflammatory agent, has demonstrated benefit in myelofibrosis (MF) and polycythemia vera (PV) patients. Combination therapy (CT) with these two agents may be more efficacious than monotherapy with either, potentially improving tolerability of interferon-α2 as well. We report the preliminary results from a phase II study of CT with pegylated interferon-α2 and ruxolitinib in 50 MPN patients (PV, n = 32; low-/intermediate-1-risk MF, n = 18), the majority (n = 47) being resistant and/or intolerant to interferon-α2 monotherapy. Objectives included remission (2013 revised criteria encompassing histologic, hematologic, and clinical responses), complete hematologic response (CHR), molecular response, and toxicity. Follow-up was 12 months. Partial remission (PR) and sustained CHR were achieved in 9% and 44% of PV patients, respectively. In MF patients, complete or partial remission was achieved in 39%, and sustained CHR in 58%. The median JAK2V617F allele burden declined significantly in both groups. Hematologic toxicity was the most common adverse event and was managed by dose reduction. Thirty-seven serious adverse events were recorded in 23 patients; the discontinuation rate was 20%. We conclude that CT with interferon-α2 and ruxolitinib is efficacious in patients with low-/intermediate-1-risk MF and, to a lesser extent, in patients with PV. These preliminary results encourage phase III studies as well as a study with CT in newly diagnosed MPN patients.

Published
2018

96. Clinical Impact of Clonal Hematopoiesis after Autologous Stem Cell Transplantation for Lymphoma:A National Population-Based Cohort Study

Author

Husby, Simon, Francesco, Favero, Nielsen, Christian, Sorensen, Betina, Baech, John, Hansen, Jakob Werner, Gonzalez, German G. R., Arboe, Bente, Andersen, Lisbeth Pernille, Hastrup, Eva Kannik, Fischer-Nielsen, Anne, Saekmose, Susanne G., Hansen, Per Boye, Christiansen, Ilse, Clasen-Linde, Erik, Knudsen, Lene Meldgaard, Grell, Kathrine, Segel, Erik Kay, Ebbesen, Lene Hyldahl, Thorsgaard, Michael, Josefsson, Par L., El-Galaly, Tarec Christoffer, Brown, Peter De Nully, Weisenfeldt, Joachim, Larsen, Thomas Stauffer, Gronbaek, Kirsten, Husby, Simon, Francesco, Favero, Nielsen, Christian, Sorensen, Betina, Baech, John, Hansen, Jakob Werner, Gonzalez, German G. R., Arboe, Bente, Andersen, Lisbeth Pernille, Hastrup, Eva Kannik, Fischer-Nielsen, Anne, Saekmose, Susanne G., Hansen, Per Boye, Christiansen, Ilse, Clasen-Linde, Erik, Knudsen, Lene Meldgaard, Grell, Kathrine, Segel, Erik Kay, Ebbesen, Lene Hyldahl, Thorsgaard, Michael, Josefsson, Par L., El-Galaly, Tarec Christoffer, Brown, Peter De Nully, Weisenfeldt, Joachim, Larsen, Thomas Stauffer, and Gronbaek, Kirsten

Published
2018

97. Treatment strategies and outcomes in diffuse large B-cell lymphoma among 1011 patients aged 75 years or older:A Danish population-based cohort study

Author

Juul, Maja Bech, Jensen, Pernille Hammershoej, Engberg, Henriette, Wehberg, Sonja, Dessau-Arp, Andriette, Haziri, Donika, Kristensen, Helene Bjoerg, Baech, Joachim, Schurmann, Lene, Clausen, Michael Roost, Valentin, Rebecca, Knudsen, Lene Meldgaard, Munksgaard, Lars, El-Galaly, Tarec Christoffer, Frederiksen, Henrik, Larsen, Thomas Stauffer, Juul, Maja Bech, Jensen, Pernille Hammershoej, Engberg, Henriette, Wehberg, Sonja, Dessau-Arp, Andriette, Haziri, Donika, Kristensen, Helene Bjoerg, Baech, Joachim, Schurmann, Lene, Clausen, Michael Roost, Valentin, Rebecca, Knudsen, Lene Meldgaard, Munksgaard, Lars, El-Galaly, Tarec Christoffer, Frederiksen, Henrik, and Larsen, Thomas Stauffer

Abstract

Background: Optimal treatment strategy for the oldest patients with diffuse large B-cell lymphoma (DLBCL) remains controversial, as this group often is precluded from clinical trials, and population-based studies are limited. Methods: All Danish DLBCL-patients ≥75 years diagnosed from 2003 to 2012 were identified, using the Danish National Lymphoma Registry (LYFO). Information regarding baseline characteristics, treatment, comorbidities and outcomes was retrieved from LYFO, the Danish National health registries and medical records. Patients were stratified by age (75–79; 80–84 and 85 + years), comorbidity score and treatment modality (standard treatment [R-CHOP/CHOP-like], less intensive regimens or palliative treatment). Findings: A total of 1011 patients were included. Standard treatment was initiated in 64%, ranging from 83% among patients aged 75–79 years to 32% among patient aged 85 + years. With standard treatment, median overall survival (OS) estimates were 4·6, 2·6, and 1·9 years for the age groups 75–79, 80–84 and 85+ years. Among patient aged 75–79 and 80–84 years, OS was superior with standard treatment, although high comorbidity scores attenuated this association. Among patients aged 85+ years, survival was not influenced by treatment intensity. Patients ≥80 years had similar OS regardless of intended (R-)CHOP dosing, whereas patients of 75–79 years scheduled for full dose had higher OS. Standard treatment was not associated with increased hospitalisation. Interpretation: Standard treatment is feasible with good outcomes in a large proportion of elderly DLBCL-patients. Planned dose reduction in patients aged ≥80 years had no negative impact on OS.

Published
2018

98. Higher rates of molecular response to Peg-IFNa in JAK2V617F vs. CALR mutant MPN patients are due to JAK1-mediated STAT1 activation and autoregulation

Author

Czech, Julia, Cordua, Sabrina, Weinbergerova, Barbora, Han, Lijuan, Schubert, Claudia, Brümmendorf, Tim H., Mayer, Jiri, Racil, Zdenek, Kubesova, Blanka, Knudsen, Trine, Sørensen, Anders, Holmstrøm, Morten, Kjær, Lasse, Skov, Vibe, Larsen, Thomas Stauffer, Hasselbalch, Hans C., Chatain, Nicolas, and Koschmieder, Steffen

Published
2017

99. Dose-dense chemoimmunotherapy and CNS prophylaxis in patients with high-risk DLBCL: a comparison of Nordic CRY-04 and CHIC studies

Author

Leppä, Sirpa, Jørgensen, Judit Meszaros, Brown, Peter De Nully, Larsen, Thomas Stauffer, Munksgaard, Lars, Janes, Robert R., Mannisto, S, K, vasala, M, Maisenholder, Meyer, P, Jerkeman, Mats, M, Björkholm, Fluge, Øystein, Jyrkkiö, Sirkku, Pedersen, L.M., Eriksson, M, and Holte, H

Abstract

Background: Survival of patients with high-risk diffuse large B-cell lymphoma (DLBCL) is suboptimal, and the risk of central nervous system (CNS) progression relatively high. We investigated the efficacy of dose-dense chemoimmunotherapy and systemic CNS prophylaxis in two completed Nordic trials including patients less than 65 years with high-risk DLBCL. We combined individual patient data from these studies to compare clinical outcome and prognostic factors in patients treated with CNS prophylaxis given in the beginning (CHIC) vs at the end (CRY-04) of therapy. Patients and methods: Inclusion criteria were age 18-65 years, primary DLBCL or grade 3 follicular lymphoma without signs of CNS involvement, WHO performance score 0-3, age adjusted International Prognostic Index (aaIPI 2-3) and/or involvement of anatomical sites associated with an increased risk for CNS recurrence (e.g. testis, facial sinuses, orbita). In CRY-04, six courses of R-CHOEP14 were followed by HD-Mtx and HD-Ara-C. In CHIC, treatment consisted of two courses of HD-Mtx in combination with R-CHOP14, followed by four courses of R-CHOEP14 and one course of R-HD-AraC. In addition, liposomal AraC was administered intrathecally at courses 1, 3 and 5. Primary end points were failure free survival (FFS; disease progression, discontinuation of protocolled therapy due to toxicity, death from any cause) at three years and CNS progression rate at 1,5 years. Secondary endpoints included progression free survival (PFS; disease progression or death from any cause) and overall survival (OS) at three years. Results: Among 303 patients enrolled in the trials (CRY-04, n=160 and CHIC, n=143), 295 (CRY-04, n=154 and CHIC, n=139) met inclusion criteria and were evaluable for baseline characteristics and primary endpoints. Median age (54 and 56 years, p=0.222), male/female ratio, stage, and aaIPI scores were comparable in the two cohorts. Three-year FFS was 63 % in CRY-04 and 77% in CHIC (p=0.018) after a median follow-up of 5 and 3 years, respectively. Cumulative incidence rates of CNS progression were 5.0% and 2.4% (p=0.22), and three-year OS 80% and 86% (p=0.508), respectively. Treatment in the CHIC reduced the risk of systemic progression (aaIPI adjusted RR=0.484, 95%CI 0.300-0.782, p=0.003). PFS benefit with CHIC vs CRY-04 was observed across pre-specified subgroups, and particularly in patients < 60 years old (p=0.007), with low proliferation index (Ki67 expression

Published
2017

100. Treatment strategies and outcomes in diffuse large B-cell lymphoma of the elderly:A danish population-based cohort study of 1.001 patients

Author

Juul, Maja Bech, Jensen, P H, Engberg, Henriette, Wehberg, Sonja, Dessau-Arp, Andriette, Haziri, D., Kristensen, Helene Bjørg, Baech, J, Schurmann, Lene, Clausen, Michael Roost, Valentin, R. X., Knudsen, Lene Melgaard, Munksgaard, Lars, El-Galaly, Tarec Christoffer, Frederiksen, Henrik, and Larsen, Thomas Stauffer

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results